Nanobiotix S.A. (NBTX)
The price, the headline numbers and the latest news, in one place.
Nanobiotix S.A. (NBTX) Stock Price, Analysis & Data
| Bid | 38.52 |
| Market Cap | 1.97B |
| Revenue (ttm) | 32.6M |
| Net Income (ttm) | -24M |
| 0.57 | |
| -0.58 | |
| n/a | |
| -113.96 | |
| P/B (ttm) | -19.17 |
| P/S (ttm) | 60.49 |
| Earnings Date | Sep 29, 2026 |
| Ask | 41.67 |
| Volume | 119,297 |
| Avg. Volume (20D) | 132,550 |
| Open | 39.01 |
| Previous Close | 40.00 |
| Day's Range | 38.43 - 40.99 |
| 52-Week Range | 8.90 - 57.14 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NBTX
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership wit...
Financial Performance
In 2025, Nanobiotix S.A.'s revenue was 29.64M, a decrease of -355.32% compared to the previous year's -11.61M. Earnings were -23.96M, a decrease of -64.83%.
Financial StatementsEarnings Surprise
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of -0.16 exceeds estimates by 0.43, with -Infinity% YoY decline.
Analysts project revenue of ... Upgrade
3 months ago · Simply Wall St.
Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share RallyNanobiotix (ENXTPA:NANO) has closed a global equity offering to fund continued development of its lead product candidate JNJ-1900 (NBTXR3). The raise followed promising early results from a Johnson & ...
